BAUSCH- Health
`
`LUMIFYTM Redness Reliever Eye Drops Honored By The National
`Association of Chain Drug Stores As Product Showcase Winner
`
`September 10, 2018
`
`NACDS Recognized LUMIFY as Best - in-Class in Healthcare and Over-the- Counter Category
`
`BRIDGEWATER, N.J., Sept. 10, 2018 / PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned
`subsidiary of Bausch Healt h Companies Inc. (NYSE/TSX: BHC), t oday announced t hat as a result of vot es from t he nat ion's largest
`retailers, LUMIFY"" brimonidine tartrat e opht halmic solution 0.025% redness reliever eye drops were named a Product Showcase winner
`in the healthcare and over-t he-counter (OTC) category at t he National Associat ion of Chain Drug Stores' (NACDS) 2018 Total St ore
`Expo. The NACDS Total Store Expo is t he largest pharmacy indust ry t rade show of the year in t he United States.
`
`"We're honored t o be recognized by NACDS wit h t he coveted Product Showcase award for LUMIFY, because it demonstrat es t hat our
`retail customers and t heir customers see t he value delivered by t his new product," said Joe Gordon, U.S. president , Bausch + Lomb.
`"Wit hin three mont hs of launching, LUMIFY is already t he number one doctor recommended brand of redness reliever eye drops and has
`already reached a market share of over 20% share of t he redness reliever category .1 We remain committed to bringing new and unique
`products like LUMIFY to market t hat meet t he evolving needs of consumers."
`
`LUMIFY is t he first and only over-the-counter eye drop developed wit h low-dose brimonidine tartrat e 0.025% for t he treat ment of
`ocular redness. In clinical t rials, LUMIFY demonstrated a strong safety and efficacy profile wit h low risk for rebound redness and 95%
`sympt om improvement seen at one minute t hat lasts up t o eight hours.
`
`LUMIFY was one of 10 other products recognized by NACDS as Product Showcase winners in categories t hat included baby care,
`consumables, home healt hcare, personal care and pharmacy products.
`
`For more information on LUMIFY, visit www.lumifydrops.com.
`
`For t he full list of Total Store Expo Product Showcase winners, click here.
`
`About NACDS
`NACDS represents t radit ional drug stores, supermarkets and mass merchants wit h pharmacies. Chains operate over 40,000
`pharmacies, and NACDS' nearly 100 chain member companies include regional chains, with a minimum of four stores, and nat ional
`companies. Chains employ nearly t hree million individuals, including 152,000 pharmacists. They fill over t hree billion prescript ions yearly,
`and help pat ients use medicines correctly and safely, while offering innovat ive services that improve patient healt h and healt hcare
`affordability. NACDS members also include more than 900 supplier partners and over 70 internat ional members represent ing 20
`countries.
`
`About Bausch + Lomb
`Bausch+ Lomb, a Bausch Health Companies Inc. company, is a leading global eye health organization t hat is solely focused on helping
`people see better t o live better. Its core businesses include over-the-count er products, dietary supplements, eye care products,
`opht halmic pharmaceuticals, contact lenses, lens care products, opht halmic surgical devices and instruments. Bausch + Lomb develops,
`manufactures and markets one of t he most comprehensive product portfolios in t he industry, which is available in more t han 100
`countries. For more information, visit www.bausch.com.
`
`About Bausch Health
`Bausch Healt h Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care
`products. We develop, manufacture and market a range of pharmaceut ical, medical device and over-the-counter products, primarily in
`the t herapeutic areas of eye healt h, gastroenterology and dermat ology. We are delivering on our commit ments as we build an innovat ive
`company dedicated to advancing global healt h. More information can be found at www.bauschhealth.com.
`
`Forward-looking Statements
`This news release may cont ain forward-looking statements which may generally be ident ified by t he use of t he words "anticipates,"
`"expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potent ial," "target," or "continue" and
`variat ions or similar expressions. These st atements are based upon t he current expect at ions and beliefs of management and are
`subject to certain risks and uncertainties t hat could cause actual results to differ materially from those described in t he forward-looking
`statements. These risks and uncertainties include, but are not limited to, risks and uncertaint ies discussed in Bausch Healt h's most
`recent annual or quarterly report and det ailed from t ime to time in Valeant's ot her filings with t he Securities and Exchange Commission
`and t he Canadian Securities Administrators, which factors are incorporat ed herein by reference. Readers are caut ioned not t o place
`undue reliance on any of t hese forward-looking st atements. These forward-looking statements speak only as of the date hereof.
`Bausch Healt h undertakes no obligation t o update any of t hese forward- looking statements to reflect events or circumstances after t he
`date of t his news release or to reflect actual outcomes, unless required by law.
`
`LUMIFY is a trademark of Bausch & Lomb Incorporated or its affiliates.
`© 2018 Bausch & Lomb Incorporated.
`LUM.0435.USA.18
`
`1 Retail dollar share for t he week ending Aug ., 26, 2018, according to IRI.
`
`Eye Therapies Exhibit 2158, 1 of 2
`Slayback v. Eye Therapies - IPR2022-00142
`
`
`
`LUMIFYTM Redness Reliever Eye Drops Honored By The National
`Association of Chain Drug Stores As Product Showcase Winner
`
`September 10, 2018
`
`NACDS Recognized LUMIFY as Best - in-Class in Healthcare and Over-the- Counter Category
`
`BRIDGEWATER, N.J., Sept. 10, 2018 / PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned
`subsidiary of Bausch Healt h Companies Inc. (NYSE/TSX: BHC), t oday announced t hat as a result of vot es from t he nat ion's largest
`retailers, LUMIFY"" brimonidine tartrat e opht halmic solution 0.025% redness reliever eye drops were named a Product Showcase winner
`in the healthcare and over-t he-counter (OTC) category at t he National Associat ion of Chain Drug Stores' (NACDS) 2018 Total St ore
`Expo. The NACDS Total Store Expo is t he largest pharmacy indust ry t rade show of the year in t he United States.
`
`"We're honored t o be recognized by NACDS wit h t he coveted Product Showcase award for LUMIFY, because it demonstrat es t hat our
`retail customers and t heir customers see t he value delivered by t his new product," said Joe Gordon, U.S. president , Bausch + Lomb.
`"Wit hin three mont hs of launching, LUMIFY is already t he number one doctor recommended brand of redness reliever eye drops and has
`already reached a market share of over 20% share of t he redness reliever category .1 We remain committed to bringing new and unique
`products like LUMIFY to market t hat meet t he evolving needs of consumers."
`
`LUMIFY is t he first and only over-the-counter eye drop developed wit h low-dose brimonidine tartrat e 0.025% for t he treat ment of
`ocular redness. In clinical t rials, LUMIFY demonstrated a strong safety and efficacy profile wit h low risk for rebound redness and 95%
`sympt om improvement seen at one minute t hat lasts up t o eight hours.
`
`LUMIFY was one of 10 other products recognized by NACDS as Product Showcase winners in categories t hat included baby care,
`consumables, home healt hcare, personal care and pharmacy products.
`
`For more information on LUMIFY, visit www.lumifydrops.com.
`
`For t he full list of Total Store Expo Product Showcase winners, click here.
`
`About NACDS
`NACDS represents t radit ional drug stores, supermarkets and mass merchants wit h pharmacies. Chains operate over 40,000
`pharmacies, and NACDS' nearly 100 chain member companies include regional chains, with a minimum of four stores, and nat ional
`companies. Chains employ nearly t hree million individuals, including 152,000 pharmacists. They fill over t hree billion prescript ions yearly,
`and help pat ients use medicines correctly and safely, while offering innovat ive services that improve patient healt h and healt hcare
`affordability. NACDS members also include more than 900 supplier partners and over 70 internat ional members represent ing 20
`countries.
`
`About Bausch + Lomb
`Bausch+ Lomb, a Bausch Health Companies Inc. company, is a leading global eye health organization t hat is solely focused on helping
`people see better t o live better. Its core businesses include over-the-count er products, dietary supplements, eye care products,
`opht halmic pharmaceuticals, contact lenses, lens care products, opht halmic surgical devices and instruments. Bausch + Lomb develops,
`manufactures and markets one of t he most comprehensive product portfolios in t he industry, which is available in more t han 100
`countries. For more information, visit www.bausch.com.
`
`About Bausch Health
`Bausch Healt h Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care
`products. We develop, manufacture and market a range of pharmaceut ical, medical device and over-the-counter products, primarily in
`the t herapeutic areas of eye healt h, gastroenterology and dermat ology. We are delivering on our commit ments as we build an innovat ive
`company dedicated to advancing global healt h. More information can be found at www.bauschhealth.com.
`
`Forward-looking Statements
`This news release may cont ain forward-looking statements which may generally be ident ified by t he use of t he words "anticipates,"
`"expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potent ial," "target," or "continue" and
`variat ions or similar expressions. These st atements are based upon t he current expect at ions and beliefs of management and are
`subject to certain risks and uncertainties t hat could cause actual results to differ materially from those described in t he forward-looking
`statements. These risks and uncertainties include, but are not limited to, risks and uncertaint ies discussed in Bausch Healt h's most
`recent annual or quarterly report and det ailed from t ime to time in Valeant's ot her filings with t he Securities and Exchange Commission
`and t he Canadian Securities Administrators, which factors are incorporat ed herein by reference. Readers are caut ioned not t o place
`undue reliance on any of t hese forward-looking st atements. These forward-looking statements speak only as of the date hereof.
`Bausch Healt h undertakes no obligation t o update any of t hese forward- looking statements to reflect events or circumstances after t he
`date of t his news release or to reflect actual outcomes, unless required by law.
`
`LUMIFY is a trademark of Bausch & Lomb Incorporated or its affiliates.
`© 2018 Bausch & Lomb Incorporated.
`LUM.0435.USA.18
`
`1 Retail dollar share for t he week ending Aug ., 26, 2018, according to IRI.
`
`Eye Therapies Exhibit 2158, 1 of 2
`Slayback v. Eye Therapies - IPR2022-00142
`
`
`
`Investor Contact:
`
`Arthur Shannon
`
`Media Contact:
`
`Lainie Keller
`
`arthur.shannon@bauschhealth.com
`
`lainie.keller@bauschhealth.com
`
`(514) 856-3855
`
`(877) 281-6642 (toll free)
`
`(908) 927-0617
`
`BAUSCH- Health
`
`BAUSCH LOMB
`
`C
`View original content to download multimedia: http ://www.prnewswire.com/news-releases/lumify-redness-reliever-eye-drops-honored-
`by-the-nationa 1-association-of-chai n-drug-stores-as-product-showcase-wi nner-300 709404. html
`
`SOURCE Bausch Health Companies Inc.
`
`Eye Therapies Exhibit 2158, 2 of 2
`Slayback v. Eye Therapies - IPR2022-00142
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
